Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Novavax (NVAX) stock in focus as company beats Q4 revenue forecasts despite an 80% drop in product sales. Read more here.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...